Effective from April 1, Russell Thirsk will be Bavarian Nordic's new chief operating officer. He takes over the role from Henrik Birk, who has chosen "to seek new challenges outside Bavarian Nordic," a press release reports.
"The timing allows a period of handover from Henrik Birk to ensure a smooth transition," Bavarian Nordic writes in the statement.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.